HHGP Senegal
The HHGP-Senegal study aims to build a standardized collection of samples and to study the correlations between immune, genetic, and microbiota phenotypes in Senegal. This project is part of the overall HHGP strategy to collect and analyze data from “healthy” subjects from several sites around the world. This is a pilot study to study the feasibility and to ensure the technical and logistical implementation of a larger scale study.
Predict UTI
We cannot predict who will experience recurrent urinary tract infection.
Urinary tract infections (UTIs) are among the most common of all infections, impacting more than 130 million people annually, worldwide. Nearly 50% of otherwise healthy adult women will have one UTI, and half of them will experience recurrent infection. Despite the extreme prevalence and economic burden on health care systems, treatment options for UTI are surprisingly limited. Antibiotics are the only first line treatment for UTI, however, antibiotic efficacy is threatened by the rapid global dissemination of multi-drug resistant uropathogens. We aimed to understand how the human immune response to infection is different to identify factors that would indicate a person is at risk of a recurrent infection. We hypothesized that the early immune response to infection determines how well a person’s immune response will ‘remember’ a second infection and that new immunotherapies that target these factors will reduce recurrent UTI.
